Sequoia Financial Advisors LLC Cuts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Sequoia Financial Advisors LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 22.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,902 shares of the medical research company’s stock after selling 1,949 shares during the period. Sequoia Financial Advisors LLC’s holdings in Edwards Lifesciences were worth $455,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter valued at $29,000. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $39,000. Peoples Bank KS acquired a new position in Edwards Lifesciences during the third quarter worth about $40,000. Finally, Versant Capital Management Inc grew its holdings in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,250 shares of company stock valued at $1,099,238. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their price target for the company from $105.00 to $75.00 in a report on Thursday, July 25th. Royal Bank of Canada dropped their price objective on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, The Goldman Sachs Group reduced their price objective on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Fifteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Stock Down 1.4 %

EW stock opened at $69.38 on Monday. The firm’s 50-day moving average is $68.09 and its two-hundred day moving average is $78.30. The company has a market capitalization of $41.79 billion, a price-to-earnings ratio of 28.55, a price-to-earnings-growth ratio of 3.00 and a beta of 1.13. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the business earned $0.59 earnings per share. On average, analysts forecast that Edwards Lifesciences Co. will post 2.61 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.